Gregory Stephanopoulos
Corporate Officer/Principal chez Massachusetts Institute of Technology
Profil
Gregory Stephanopoulos is the founder of Manus Bio, Inc. which was founded in 2011.
He is also the founder of Semprus BioSciences Corp.
Currently, he is a Professor at Harvard University and Massachusetts Institute of Technology.
He previously worked as a Member at Technical University of Denmark.
Dr. Stephanopoulos has a graduate degree from the University of Florida, a doctorate degree from the University of Minnesota, and an undergraduate degree from National Technical University of Athens.
Postes actifs de Gregory Stephanopoulos
| Sociétés | Poste | Début |
|---|---|---|
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Anciens postes connus de Gregory Stephanopoulos
| Sociétés | Poste | Fin |
|---|---|---|
| Technical University of Denmark | Corporate Officer/Principal | - |
Manus Bio, Inc.
 Manus Bio, Inc. Pharmaceuticals: OtherHealth Technology Manus Bio, Inc. supplies natural plant ingredients. It uses advanced fermentation technology for manufacturing complex, bioactive natural products as flavors, fragrances, food ingredients, biopesticides, and pharmaceuticals. The company was founded by Ajikumar Parayil and Gregory Stephanopoulos in 2011 and is headquartered in Waltham, MA. | Fondateur | - |
Semprus BioSciences Corp.
 Semprus BioSciences Corp. Pharmaceuticals: GenericHealth Technology Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Their innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Their current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification. Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of their Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, their technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. They have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices. | Fondateur | - |
Formation de Gregory Stephanopoulos
| University of Florida | Graduate Degree |
| University of Minnesota | Doctorate Degree |
| National Technical University of Athens | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Semprus BioSciences Corp.
Semprus BioSciences Corp. Pharmaceuticals: GenericHealth Technology Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Their innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Their current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification. Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of their Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, their technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. They have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices. | Health Technology |
Manus Bio, Inc.
Manus Bio, Inc. Pharmaceuticals: OtherHealth Technology Manus Bio, Inc. supplies natural plant ingredients. It uses advanced fermentation technology for manufacturing complex, bioactive natural products as flavors, fragrances, food ingredients, biopesticides, and pharmaceuticals. The company was founded by Ajikumar Parayil and Gregory Stephanopoulos in 2011 and is headquartered in Waltham, MA. | Health Technology |